The American Journal of Managed Care53m
Evolent’s Wonsettler Sees Outcomes-Based Reimbursement as “A Healthy Tool”
Terra Wonsettler, PharmD, MBA, vice president of pharmacy for Evolent, discusses the recent HHS OIG report that stemmed from ...
The American Journal of Managed Care4d
OIG Report Seeks Better Oversight, Records for FDA’s Accelerated Approvals
Amid the uproar over the firing of 18 inspectors general, a report offering a coda to the aducanumab approval episode has ...
Indiatimes22d
Inhaling this gas could help treat Alzheimer's disease, study suggests
It has also given accelerated approval for aducanumab (Aduhelm). While three drugs have been approved, the treatments didn't prove to be as effective as thought. Aduhelm was withdrawn from the market.
MedPage Today23d
HHS Inspector General Raises Concerns Over FDA's Accelerated Approvals
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA ...
Seeking Alpha24d
Sarepta, Biogen drugs with accelerated approval under fire in FDA report
The Sarepta and Biogen therapies mentioned are, respectively, Exondys 51 (eteplirsen) and Aduhelm (aducanumab). They are used for Duchenne muscular dystrophy and Alzheimer's disease. The FDA's ...
WDRB25d
Up to 4 in 10 people could develop dementia after 55. What you can do to lower your risk
WASHINGTON (AP) — About a million Americans a year are expected to develop dementia by 2060, roughly double today’s toll, researchers reported Monday. That estimate is based on a new study ...
Salon27d
Why Alzheimer’s scientists are rethinking the amyloid hypothesis
In June 2021, the Food and Drug Administration approved aducanumab, an amyloid beta-targeted drug, under the “accelerated approval” program for patients diagnosed with Alzheimer’s.